Invasive giant prolactinoma with loss of therapeutic response to cabergoline: Expression of angiogenic markers

Mostrar otras versiones (1)

The present study reports the case of a 70-year-old Caucasian man who was referred to the Military Hospital of Buenos Aires for evaluation of a giant sellar-extrasellar mass with extension in the right temporal lobe and compression of the third ventricle. Patient was initially responsive to cabergol...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Mallea-Gil, M.S
Otros Autores: Cristina, C., Perez-Millan, M.I, Villafañe, A.M.R, Ballarino, C., Stalldecker, G., Becu-Villalobos, D.
Formato: Capítulo de libro
Lenguaje:Inglés
Publicado: 2009
Materias:
AMNESIA
Acceso en línea:Registro en Scopus
DOI
Handle
Registro en la Biblioteca Digital
Aporte de:Registro referencial: Solicitar el recurso aquí
Biblioteca Central Dr. Luis F. Leloir (FCEN) de Universidad de Buenos Aires
LEADER 15548caa a22016817a 4500
001 PAPER-23217
003 AR-BaUEN
005 20230518205452.0
008 190411s2009 xx ||||fo|||| 00| 0 eng|d
024 7 |2 scopus  |a 2-s2.0-66349120511 
024 7 |2 cas  |a cabergoline, 81409-90-7; growth hormone, 36992-73-1, 37267-05-3, 66419-50-9, 9002-72-6; octreotide, 83150-76-9; somatomedin C, 67763-96-6; vasculotropin, 127464-60-2; prolactin, 12585-34-1, 50647-00-2, 9002-62-4; Antineoplastic Agents; Ergolines; Prolactin, 9002-62-4; Tumor Markers, Biological; cabergoline, 81409-90-7 
040 |a Scopus  |b spa  |c AR-BaUEN  |d AR-BaUEN 
030 |a ENPAF 
100 1 |a Mallea-Gil, M.S. 
245 1 0 |a Invasive giant prolactinoma with loss of therapeutic response to cabergoline: Expression of angiogenic markers 
260 |c 2009 
270 1 0 |m Becu-Villalobos, D.; Instituto de Biología y Medicina Experimental, CONICET, Ciudad Autónoma, Vuelta de Obligado 2490, Buenos Aires 1428, Argentina; email: dbecu@dna.uba.ar 
506 |2 openaire  |e Política editorial 
504 |a Corsello, S.M., Ubertini, G., Altomare, M., Lovicu, R.M., Migneco, M.G., Rota, C.A., Colosimo, C., Giant prolactinomas in men: Efficacy of cabergoline treatment (2003) Clinical Endocrinology, 58 (5), pp. 662-670. , DOI 10.1046/j.1365-2265.2003.01770.x 
504 |a Lundin, P., Pedersen, F., Volume of pituitary macroadenomas: Assessment by MRI (1992) J Comput Assist Tomogr, 16, pp. 519-528. , doi:10.1097/00004728-199207000-00004 
504 |a Molitch, M.E., Pharmacologic resistance in prolactinoma patients (2005) Pituitary, 8 (1), pp. 43-52. , DOI 10.1007/s11102-005-5085-2, Special Issie on Pathogenesis, Diagnosis and Clinics of Prolactinomas 
504 |a Pernicone, P.J., Scheithauer, B.W., Sebo, T.J., Kovacs, K.T., Horvath, E., Young Jr., W.F., Lloyd, R.V., Schoene, W.C., Pituitary carcinoma: A clinicopathologic study of 15 cases (1997) Cancer, 79 (4), pp. 804-812. , DOI 10.1002/(SICI)1097-0142(19970215)79:4<804::AID-CNCR18>3.0.CO;2- 3 
504 |a Delgrange, E., Crabbe, J., Donckier, J., Late development of resistance to bromocriptine in a patient with macroprolactinoma (1998) Hormone Research, 49 (5), pp. 250-253. , DOI 10.1159/000023180 
504 |a McCall, D., Hunter, S.J., Cooke, R.S., Herron, B., Sheridan, B., Atkinson, A.B., Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma [2] (2007) Clinical Endocrinology, 66 (1), pp. 149-150. , DOI 10.1111/j.1365-2265.2006.02686.x 
504 |a Turner, H.E., Nagy, Zs., Gatter, K.C., Esiri, M.M., Harris, A.L., Wass, J.A.H., Angiogenesis in pituitary adenomas - Relationship to endocrine function, treatment and outcome (2000) Journal of Endocrinology, 165 (2), pp. 475-481 
504 |a Mucha, S.A., Melen-Mucha, G., Godlewski, A., Stepien, H., Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat (2007) Virchows Archiv, 450 (3), pp. 335-341. , DOI 10.1007/s00428-006-0351-x 
504 |a Pawlikowski, M., Grochal, M., Kulig, A., Zielinski, K., Stepien, H., Kunert-Radek, J., Mucha, S., The effect of angiotensin II receptor antagonists on diethylstilbestrol- induced vascular changes in the rat anterior pituitary gland: A quantitative evaluation (1996) Histology and Histopathology, 11 (4), pp. 909-913 
504 |a Stepien, H., Grochal, M., Zielinski, K.W., Mucha, S., Kunert-Radek, J., Kulig, A., Inhibitory effects of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fischer 344 rats (1996) J Endocrinol, 150, pp. 99-106. , doi:10.1677/joe.0.1500099 
504 |a Gorczyca, W., Hardy, J., Microadenomas of the human pituitary and their vascularization (1988) Neurosurgery, 22, pp. 1-6. , doi:10.1097/ 00006123-198801010-198900001 
504 |a De La Torre, N.G., Wass, J.A., Turner, H.E., Morphologic changes and molecular regulation of angiogenesis in pituitary adenomas (2004) Front Horm Res, 32, pp. 133-145. , doi:10.1159/000079042 
504 |a Ferrara, N., Davis-Smyth, T., The biology of vascular endothelial growth factor (1997) Endocrine Reviews, 18 (1), pp. 4-25. , DOI 10.1210/er.18.1.4 
504 |a Bikfalvi, A., Klein, S., Pintucci, G., Rifkin, D.B., Biological roles of fibroblast growth factor-2 (1997) Endocrine Reviews, 18 (1), pp. 26-45. , DOI 10.1210/er.18.1.26 
504 |a Komorowski, J., Jankewicz, J., Stepien, H., Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (sIL-2R) concentrations in peripheral blood as markers of pituitary tumours (2000) Cytobios, 101, pp. 151-159 
504 |a Cristina, C., Diaz-Torga, G., Gongora, A., Guida, M.C., Perez-Millan, M.I., Baldi, A., Fibroblast Growth Factor-2 in hyperplastic pituitaries of D2R knockout female mice (2007) Am J Physiol Endocrinol Metab, 293, pp. E1341-E1351. , doi:10.1152/ ajpendo.00260.2007 
504 |a Cristina, C., Diaz-Torga, G., Baldi, A., Gongora, A., Rubinstein, M., Low, M.J., Becu-Villalobos, D., Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice (2005) Endocrinology, 146 (7), pp. 2952-2962. , http://endo.endojournals.org/cgi/reprint/146/7/2952, DOI 10.1210/en.2004-1445 
504 |a Kim, K., Yoshida, D., Teramoto, A., Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in pituitary adenomas (2005) Endocrine Pathology, 16 (2), pp. 115-121. , DOI 10.1385/EP:16:2:115 
504 |a Minematsu, T., Suzuki, M., Sanno, N., Takekoshi, S., Teramoto, A., Osamura, R.Y., PTTG overexpression is correlated with angiogenesis in human pituitary adenomas (2006) Endocrine Pathology, 17 (2), pp. 143-153. , DOI 10.1385/EP:17:2:143, PII EP172143 
504 |a Piroli, G., Torres, A., Grillo, C., Lux-Lantos, V., Aoki, A., De Nicola, A.F., Mechanisms in progestin antagonism of pituitary tumorigenesis (1998) J Steroid Biochem Mol Biol, 64, pp. 59-67. , doi:10.1016/ S0960-0760(97)00139-148 
504 |a Brue, T., Pellegrini, I., Priou, A., Morange, I., Jaquet, P., Prolactinomas and resistance to dopamine agonists (1992) Horm Res, 38, pp. 84-89 
504 |a Delgrange, E., Trouillas, J., Maiter, D., Donckier, J., Tourniaire, J., Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study (1997) Journal of Clinical Endocrinology and Metabolism, 82 (7), pp. 2102-2107. , DOI 10.1210/jc.82.7.2102 
504 |a Maraschini, C., Moro, M., Masala, A., Toja, P., Alagna, S., Brunani, A., Chronic treatment with parlodel LAR of patients with prolactin-secreting tumours. Different responsiveness of microand macroprolactinomas (1991) Acta Endocrinol (Copenhagen), 125, pp. 494-501 
504 |a Caccavelli, L., Morange-Ramos, I., Kordon, C., Jaquet, P., Enjalbert, A., Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas (1996) J Neuroendocrinol, 8, pp. 737-746. , doi:10.1046/j.1365-2826.1996.04902.x 
504 |a Caccavelli, L., Feron, F., Morange, I., Rouer, E., Benarous, R., Dewailly, D., Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas (1994) Neuroendocrinology, 60, pp. 314-322. , doi:10.1159/000126764 
504 |a Ferrara, N., Gerber, H.-P., LeCouter, J., The biology of VEGF and its receptors (2003) Nature Medicine, 9 (6), pp. 669-676. , DOI 10.1038/nm0603-669 
504 |a Schechter, J., Goldsmith, P., Wilson, C., Weiner, R., Morphological evidence for the presence of arteries in human prolactinomas (1988) J Clin Endocrinol Metab, 67, pp. 713-719 
504 |a Jugenburg, M., Kovacs, K., Stefaneanu, L., Scheithauer, B.W., Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: A quantitative morphologic study (1995) Endocr Pathol, 6, pp. 115-124. , doi:10.1007/BF02739874 
504 |a Lloyd, R.V., Scheithauer, B.W., Kuroki, T., Vidal, S., Kovacs, K., Stefaneanu, L., Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas (1999) Endocr Pathol, 10, pp. 229-235. , doi:10.1007/BF02738884 
504 |a McCabe, C.J., Boelaert, K., Tannahill, L.A., Heaney, A.P., Stratford, A.L., Khaira, J.S., Vascular endothelial growth factor, its receptor KDR/ Flk-1, and pituitary tumor transforming gene in pituitary tumors (2002) J Clin Endocrinol Metab, 87, pp. 4238-4244. , doi:10.1210/jc.2002-020309 
504 |a Arita, K., Kurisu, K., Tominaga, A., Sugiyama, K., Eguchi, K., Hama, S., Relationship between intratumoral hemorrhage and overexpression of vascular endothelial growth factor (VEGF) in pituitary adenoma (2004) Hiroshima J Med Sci, 53, pp. 23-27 
504 |a Basu, S., Nagy, J.A., Pal, S., Vasile, E., Eckelhoefer, I.A., Bliss, V.S., Manseau, E.J., Mukhopadhyay, D., The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor (2001) Nature Medicine, 7 (5), pp. 569-574. , DOI 10.1038/87895 
504 |a Chakroborty, D., Sarkar, C., Mitra, R.B., Banerjee, S., Dasgupta, P.S., Basu, S., Depleted dopamine in gastric cancer tissues: Dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis (2004) Clin Cancer Res, 10, pp. 4349-4356. , doi:10.1158/1078-0432. CCR-04-0059 
504 |a Cristina, C., Garcia-Tornadu, I., Diaz-Torga, G., Rubinstein, M., Low, M.J., Becu-Villalobos, D., Dopaminergic D2 receptor knockout mouse: An animal model of prolactinoma (2006) Frontiers of Hormone Research, 35, pp. 50-63. , DOI 10.1159/000094308, Pituitary Today: Molecular, Physiological and Clinical Aspects 
504 |a Gaffey, T.A., Scheithauer, B.W., Lloyd, R.V., Burger, P.C., Robbins, P., Fereidooni, F., Corticotroph carcinoma of the pituitary: A clinicopathological study. Report of four cases (2002) J Neurosurg, 96, pp. 352-360 
504 |a Gurlek, A., Karavitaki, N., Ansorge, O., Wass, J.A.H., What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics (2007) European Journal of Endocrinology, 156 (2), pp. 143-153. , DOI 10.1530/eje.1.02339 
504 |a Oliveira, M.C., Marroni, C.P., Pizarro, C.B., Pereira-Lima, J.F., Barbosa- Coutinho, L.M., Ferreira, N.P., Expression of p53 protein in pituitary adenomas (2002) Braz J Med Biol Res, 35, pp. 561-565 
520 3 |a The present study reports the case of a 70-year-old Caucasian man who was referred to the Military Hospital of Buenos Aires for evaluation of a giant sellar-extrasellar mass with extension in the right temporal lobe and compression of the third ventricle. Patient was initially responsive to cabergoline with reduction of prolactin levels and shrinkage of tumor burden for at least 36 months. Thereafter, prolactin levels and tumor size increased even though cabergoline dosage was increased. Transcraneal surgery was performed at 56 months of treatment. Prolactin levels and tumor proliferation did not subside and the patient died 14 months later. High GH and IGF-I levels were observed in the late stages of tumor development, with no evidence of acromegalic features. Immunohisto-chemistry of the excised tumor revealed strong immunore-activity for VEGF and FGF-2, two potent angiogenic factors, and CD31 (an endothelial marker) indicating high vascularization of the adenoma. © Humana Press Inc. 2009.  |l eng 
536 |a Detalles de la financiación: Fundación Florencio Fiorini 
536 |a Detalles de la financiación: Fundación Alberto J. Roemmers 
536 |a Detalles de la financiación: Agencia Nacional de Promoción Científica y Tecnológica 
536 |a Detalles de la financiación: Consejo Nacional de Investigaciones Científicas y Técnicas 
536 |a Detalles de la financiación: Acknowledgements This work was supported by grants from CONICET, Fundación Alberto J. Roemmers, Fundación Fiorini, and Agencia Nacional de Promoción Científica y Técnica, Buenos Aires, Argentina (DBV). 
593 |a Hospital Militar Central, Luis Maria Campos 726, Ciudad Autónoma, Buenos Aires 1426, Argentina 
593 |a Instituto de Biología y Medicina Experimental, CONICET, Ciudad Autónoma, Vuelta de Obligado 2490, Buenos Aires 1428, Argentina 
593 |a Hospital General de Agudos Pirovano, Ciudad Autónoma, Monroe 3555, Buenos Aires, Argentina 
690 1 0 |a DOPAMINE AGONIST RESISTANCE 
690 1 0 |a FGF 
690 1 0 |a IGFI 
690 1 0 |a KI67 
690 1 0 |a PROLACTINOMA 
690 1 0 |a VEGF 
690 1 0 |a CABERGOLINE 
690 1 0 |a CD31 ANTIGEN 
690 1 0 |a FIBROBLAST GROWTH FACTOR 2 
690 1 0 |a GROWTH HORMONE 
690 1 0 |a KI 67 ANTIGEN 
690 1 0 |a OCTREOTIDE 
690 1 0 |a SOMATOMEDIN C 
690 1 0 |a VASCULOTROPIN 
690 1 0 |a ANTINEOPLASTIC AGENT 
690 1 0 |a CABERGOLINE 
690 1 0 |a ERGOLINE DERIVATIVE 
690 1 0 |a PROLACTIN 
690 1 0 |a TUMOR MARKER 
690 1 0 |a AGED 
690 1 0 |a ARTICLE 
690 1 0 |a ATTENTION DISTURBANCE 
690 1 0 |a BRAIN THIRD VENTRICLE 
690 1 0 |a CANCER INVASION 
690 1 0 |a CASE REPORT 
690 1 0 |a DRUG DOSE INCREASE 
690 1 0 |a FATALITY 
690 1 0 |a GAIT DISORDER 
690 1 0 |a GROWTH HORMONE RELEASE 
690 1 0 |a HEADACHE 
690 1 0 |a HUMAN 
690 1 0 |a IMMUNOHISTOCHEMISTRY 
690 1 0 |a MALE 
690 1 0 |a PRIORITY JOURNAL 
690 1 0 |a PROLACTINOMA 
690 1 0 |a SLEEP DISORDER 
690 1 0 |a TEMPORAL LOBE 
690 1 0 |a TUMOR GROWTH 
690 1 0 |a TUMOR VASCULARIZATION 
690 1 0 |a VISUAL IMPAIRMENT 
690 1 0 |a BLOOD 
690 1 0 |a DRUG RESISTANCE 
690 1 0 |a GENETICS 
690 1 0 |a HYPOPHYSIS TUMOR 
690 1 0 |a HYPOTHYROIDISM 
690 1 0 |a METABOLISM 
690 1 0 |a NEOVASCULARIZATION (PATHOLOGY) 
690 1 0 |a NUCLEAR MAGNETIC RESONANCE IMAGING 
690 1 0 |a PATHOLOGY 
690 1 0 |a PROLACTINOMA 
690 1 0 |a AGED 
690 1 0 |a ANTINEOPLASTIC AGENTS 
690 1 0 |a DRUG RESISTANCE, NEOPLASM 
690 1 0 |a ERGOLINES 
690 1 0 |a HUMANS 
690 1 0 |a HYPOTHYROIDISM 
690 1 0 |a IMMUNOHISTOCHEMISTRY 
690 1 0 |a MAGNETIC RESONANCE IMAGING 
690 1 0 |a MALE 
690 1 0 |a NEOVASCULARIZATION, PATHOLOGIC 
690 1 0 |a PITUITARY NEOPLASMS 
690 1 0 |a PROLACTIN 
690 1 0 |a PROLACTINOMA 
690 1 0 |a TUMOR MARKERS, BIOLOGICAL 
650 1 7 |2 spines  |a AMNESIA 
700 1 |a Cristina, C. 
700 1 |a Perez-Millan, M.I. 
700 1 |a Villafañe, A.M.R. 
700 1 |a Ballarino, C. 
700 1 |a Stalldecker, G. 
700 1 |a Becu-Villalobos, D. 
773 0 |d 2009  |g v. 20  |h pp. 35-40  |k n. 1  |p Endocr. Pathol.  |x 10463976  |t Endocrine Pathology 
856 4 1 |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-66349120511&doi=10.1007%2fs12022-009-9057-3&partnerID=40&md5=fcd11af7818453f0c0a44400e559addb  |y Registro en Scopus 
856 4 0 |u https://doi.org/10.1007/s12022-009-9057-3  |y DOI 
856 4 0 |u https://hdl.handle.net/20.500.12110/paper_10463976_v20_n1_p35_MalleaGil  |y Handle 
856 4 0 |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_10463976_v20_n1_p35_MalleaGil  |y Registro en la Biblioteca Digital 
961 |a paper_10463976_v20_n1_p35_MalleaGil  |b paper  |c PE 
962 |a info:eu-repo/semantics/article  |a info:ar-repo/semantics/artículo  |b info:eu-repo/semantics/publishedVersion 
999 |c 84170 

Ejemplares similares